In addition to CG001419, Cullgen continues the advancement of CG009301, a GSPT1 degrader being studied in a Phase 1 trial for the treatment of blood cancers, as well as progressing its pipeline of pre ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for ...

Despite growing interest in sustainable eating, the plant-based meat sector faces cultural, social and psychological hurdles ...